{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:01:39Z","timestamp":1781103699519,"version":"3.54.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["302962"],"award-info":[{"award-number":["302962"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["1084890"],"award-info":[{"award-number":["1084890"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["750615"],"award-info":[{"award-number":["750615"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006087","name":"Direcci\u00f3n General de Asuntos del Personal Acad\u00e9mico, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.arcmed.2022.11.008","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T03:57:09Z","timestamp":1669780629000},"page":"794-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2402-2135","authenticated-orcid":false,"given":"Julian A.","family":"Gaj\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3816-1614","authenticated-orcid":false,"given":"Angel","family":"Juarez-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara\u00ed G.","family":"De Le\u00f3n Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5317-4731","authenticated-orcid":false,"given":"Cristina","family":"Aguilar Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Mantilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel M.","family":"Fuentes-Panan\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Bonifaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2022.11.008_bib0001","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0002","first-page":"170","article-title":"Skin Cancer in Skin of Color","volume":"21","author":"Bradford","year":"2009","journal-title":"Dermatol Nurs"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0003","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1039\/d0pp90011g","article-title":"Environmental effects of stratospheric ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2019","volume":"19","author":"Bernhard","year":"2020","journal-title":"Photochem Photobiol Sci"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0004","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-0-387-77574-6_8","article-title":"Epidemiology of melanoma and nonmelanoma skin cancer\u2013the role of sunlight","volume":"624","author":"Leiter","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.hoc.2018.09.005","article-title":"Cutaneous Melanoma\u2014A Review in Detection, Staging, and Management","volume":"33","author":"Hartman","year":"2019","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0006","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.3390\/ijms23126388","article-title":"The Treatment of Advanced Melanoma: Therapeutic Update","volume":"23","author":"Villani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0007","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/2326-6066.CIR-20-0983","article-title":"TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma","volume":"9","author":"Hodi","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0008","doi-asserted-by":"crossref","unstructured":"Kibbi N, Kluger H, Choi JN. Melanoma: Clinical Presentations. In: Kaufman HL, Mehnert JM, editors. Melanoma [Internet]. Cham: Springer International Publishing 2016. pp. 107\u201329. (Cancer Treatment and Research). Available from: doi:10.1007\/978-3-319-22539-5_4. (Accessed July 15, 2022).","DOI":"10.1007\/978-3-319-22539-5_4"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0010","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/0190-9622(95)90294-5","article-title":"Benign melanocytic lesions: Risk markers or precursors of cutaneous melanoma?","volume":"33","author":"Skender-Kalnenas","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0011","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/0190-9622(92)70133-Z","article-title":"Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma: Results of a case control study in melanoma patients and nonmelanoma control subjects","volume":"26","author":"Kr\u00fcger","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0012","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11864-006-0011-z","article-title":"Epidemiology and prevention of cutaneous melanoma","volume":"7","author":"Demierre","year":"2006","journal-title":"Curr Treat Options in Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0013","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0014","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.29727","article-title":"Uveal melanoma: From diagnosis to treatment and the science in between","volume":"122","author":"Chattopadhyay","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2133.2007.08031.x","article-title":"Acral lentiginous melanoma: histopathological prognostic features of 121 cases","volume":"157","author":"Phan","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0016","first-page":"246","article-title":"Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988\u201393","volume":"8","author":"Cress","year":"1997","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0017","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaad.2020.08.097","article-title":"The ongoing racial disparities in melanoma: An analysis of the Surveillance, Epidemiology, and End Results database (1975\u20132016)","volume":"84","author":"Qian","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0018","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1524-4725.1994.tb03711.x","article-title":"Acral Lentiginous Melanoma: A Histological Type without Prognostic Significance","volume":"20","author":"Cascinelli","year":"1994","journal-title":"J Dermatol Surg Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0019","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11864-018-0560-y","article-title":"Diagnosis and Management of Acral Lentiginous Melanoma","volume":"19","author":"Nakamura","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.720044","article-title":"Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral\/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial","volume":"11","author":"Mao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0021","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/pcmr.12885","article-title":"Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease","volume":"34","author":"Basurto-Lozada","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0022","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/1346-8138.13834","article-title":"Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan","volume":"44","author":"Wada","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0023","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1245\/s10434-020-08418-5","article-title":"The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma","volume":"27","author":"Wei","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0024","unstructured":"Cancer Today. Available from: https:\/\/gco.iarc.fr\/today\/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0. (Accessed September 2, 2022)."},{"key":"10.1016\/j.arcmed.2022.11.008_bib0025","unstructured":"Cancer Tomorrow. Available from: https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/tables?types=1&sexes=0&mode=population&group_populations=0&multiple_populations=1&multiple_cancers=0&cancers=16&populations=160_392_410_484_840_906_916_921_922_931_991_992_995_994_993_996_935_984_982_981&single_unit=50. (Accessed August 18, 2022)."},{"issue":"4\/2019","key":"10.1016\/j.arcmed.2022.11.008_bib0026","doi-asserted-by":"crossref","first-page":"26","DOI":"10.12948\/issn14531305\/23.4.2019.03","article-title":"The Role of Economic and Political Features in Classification of Countries-in-Transition by Human Development Index","volume":"23","author":"Kinnunen","year":"2019","journal-title":"IE"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0027","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jaad.2004.04.045","article-title":"Genetic testing in hereditary melanoma","volume":"51","author":"Tsao","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0028","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","article-title":"Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment","volume":"30","author":"Ahmed","year":"2020","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0029","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/ijc.22453","article-title":"International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review","volume":"120","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/pcmr.12865","article-title":"Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling","volume":"33","author":"Zou","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0031","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","article-title":"Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity","volume":"11","author":"Newell","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0032","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.5213","article-title":"Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities","volume":"247","author":"Rabbie","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0033","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 2015;161:1681\u20131696.","DOI":"10.1016\/j.cell.2015.05.044"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0034","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.1158\/1078-0432.CCR-17-0070","article-title":"Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4\/6 Inhibitors in Targeted Therapy","volume":"23","author":"Kong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0035","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","article-title":"Large-scale analysis of KIT aberrations in Chinese patients with melanoma","volume":"17","author":"Kong","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0036","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1158\/1078-0432.CCR-19-0475","article-title":"Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma","volume":"25","author":"Yu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0037","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/bjd.19680","article-title":"Comparative whole-exome sequencing of an ultra-late recurrent malignant melanoma","volume":"184","author":"Nakamura","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100002","article-title":"Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment","volume":"6","author":"Byeon","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0039","doi-asserted-by":"crossref","first-page":"106132","DOI":"10.18632\/oncotarget.22190","article-title":"Immune system and melanoma biology: a balance between immunosurveillance and immune escape","volume":"8","author":"Passarelli","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0040","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.semcancer.2019.08.002","article-title":"Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment","volume":"59","author":"Marzagalli","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0041","series-title":"Advances in Immunology","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-800267-4.00003-1","article-title":"Chapter Three - Recognition of Tumors by the Innate Immune System and Natural Killer Cells","author":"Marcus","year":"2014"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0042","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0043","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1172\/JCI42002","article-title":"Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma","volume":"120","author":"Eyles","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0044","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-21-3145","article-title":"Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy","volume":"28","author":"Li","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0045","first-page":"e78616","article-title":"Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments","volume":"11","author":"He","year":"2022"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0046","doi-asserted-by":"crossref","first-page":"eabi5072","DOI":"10.1126\/sciimmunol.abi5072","article-title":"Spatially mapping the immune landscape of melanoma using imaging mass cytometry","volume":"7","author":"Moldoveanu","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0047","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0048","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-18-2652","article-title":"Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma","volume":"25","author":"Wong","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0049","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s40425-019-0675-0","article-title":"Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma","volume":"7","author":"Wong","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9775736","article-title":"A machine learning workflow of multiplexed immunofluorescence images to interrogate activator and tolerogenic profiles of conventional type 1 dendritic cells infiltrating melanomas of disease-free and metastatic patients","volume":"2022","author":"De Le\u00f3n-Rodr\u00edguez","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0051","doi-asserted-by":"crossref","first-page":"E8359","DOI":"10.3390\/ijms21218359","article-title":"The Influence of Tumor Microenvironment on Immune Escape of Melanoma","volume":"21","author":"Simiczyjew","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0052","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41591-018-0217-1","article-title":"Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma","volume":"24","author":"Cerezo","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0053","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1054\/bjps.2001.3745","article-title":"UK guidelines for the management of cutaneous melanoma","volume":"55","author":"Bishop","year":"2002","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0054","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/DSS.0000000000000648","article-title":"Excision Margins for Melanoma In Situ on the Head and Neck","volume":"42","author":"Felton","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0055","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/17460441.2021.1942834","article-title":"Advances in the discovery and development of melanoma drug therapies","volume":"16","author":"Chanda","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0056","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Coit","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0057","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0058","unstructured":"Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | British Journal of Cancer. Available from: https:\/\/www.nature.com\/articles\/6603291. (Accessed August 22, 2022)."},{"key":"10.1016\/j.arcmed.2022.11.008_bib0059","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1479-5876-10-246","article-title":"Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)","volume":"10","author":"Gajewski","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0060","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clml.2015.02.018","article-title":"Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients with Refractory Hematologic Malignancies","volume":"15","author":"Badar","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0061","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II Study of the MEK1\/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0062","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation\u2013Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0063","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/1346-8138.14210","article-title":"Phase 1\/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma","volume":"45","author":"Yamazaki","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0064","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0065","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin","volume":"31","author":"Hodi","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0066","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3747\/co.27.5223","article-title":"A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Current Oncology"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0067","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-019-0607-8","article-title":"Targeted Therapy and Immunotherapy for Melanoma in Japan","volume":"20","author":"Namikawa","year":"2019","journal-title":"Curr Treat Options in Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0068","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/JLB.MR0618-241RR","article-title":"OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy","volume":"105","author":"Le\u00f3n-Letelier","year":"2019","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0069","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0070","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.arcmed.2022.11.008_bib0071","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma","volume":"39","author":"Wolchok","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0072","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0073","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0074","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0076","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctrv.2017.08.009","article-title":"Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review","volume":"60","author":"Heppt","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100325","article-title":"Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)","volume":"6","author":"Nakamura","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0078","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","article-title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients","volume":"31","author":"Nakamura","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0079","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00280-016-3237-x","article-title":"Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)","volume":"79","author":"Yamazaki","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0081","article-title":"Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions","author":"Mao","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0082","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0083","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1470-2045(10)70288-6","article-title":"Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial","volume":"12","author":"Hansson","year":"2011","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0084","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejca.2012.07.018","article-title":"Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study","volume":"49","author":"Grob","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0085","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ejca.2011.03.019","article-title":"A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon \u03b1-2b in high-risk acral melanoma patients","volume":"47","author":"Mao","year":"2011","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.arcmed.2022.11.008_bib0086","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","volume":"6","author":"Atkins","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0087","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0088","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","article-title":"Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients","volume":"16","author":"Besser","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0089","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2007.11.9941","article-title":"Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group","volume":"26","author":"Testori","year":"2008","journal-title":"JCO"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0090","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0091","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0092","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0093","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1186\/s12885-022-09896-4","article-title":"Neoadjuvant nivolumab\u202f+\u202fT-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial","volume":"22","author":"Rohaan","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0094","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0095","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1158\/2326-6066.CIR-19-0835","article-title":"Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas","volume":"8","author":"Edwards","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0096","article-title":"Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF\/MEK inhibitors in patients with BRAF mutant metastatic melanoma","volume":"10","author":"da","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.arcmed.2022.11.008_bib0097","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat Med"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440922001503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440922001503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:36:21Z","timestamp":1778675781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440922001503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":97,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0188440922001503"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2022.11.008","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2022.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}